{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:01:38Z","timestamp":1794895298783,"version":"4.9.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"L.D. is supported by the following funding sources: Aarhus University, The Danish Cancer Biobank, The Danish Cancer Society.","id":[{"id":"https:\/\/ror.org\/03ytt7k16","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variable clinical outcomes. Here, we perform an integrative multi-omics analysis of patients diagnosed with NMIBC (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009834). Transcriptomic analysis identifies four classes (1, 2a, 2b and 3) reflecting tumor biology and disease aggressiveness. Both transcriptome-based subtyping and the level of chromosomal instability provide independent prognostic value beyond established prognostic clinicopathological parameters. High chromosomal instability, p53-pathway disruption and APOBEC-related mutations are significantly associated with transcriptomic class 2a and poor outcome. RNA-derived immune cell infiltration is associated with chromosomally unstable tumors and enriched in class 2b. Spatial proteomics analysis confirms the higher infiltration of class 2b tumors and demonstrates an association between higher immune cell infiltration and lower recurrence rates. Finally, the independent prognostic value of the transcriptomic classes is documented in 1228 validation samples using a single sample classification tool. The classifier provides a framework for biomarker discovery and for optimizing treatment and surveillance in next-generation clinical trials.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-22465-w","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T07:36:09Z","timestamp":1618558569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":367,"title":["An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5280-7306","authenticated-orcid":false,"given":"Sia Viborg","family":"Lindskrog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Prip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1347-7724","authenticated-orcid":false,"given":"Philippe","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0516-9564","authenticated-orcid":false,"given":"Ann","family":"Taber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5222-2586","authenticated-orcid":false,"given":"Clarice S.","family":"Groeneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8057-6277","authenticated-orcid":false,"given":"Karin","family":"Birkenkamp-Demtr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen Bjerggaard","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Strandgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4856-4086","authenticated-orcid":false,"given":"Iver","family":"Nordentoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7201-3933","authenticated-orcid":false,"given":"Emil","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateo","family":"Sokac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1613-9587","authenticated-orcid":false,"given":"Nicolai J.","family":"Birkbak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Maretty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregers G.","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid C.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Weyerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Oliver","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Horstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7869-0473","authenticated-orcid":false,"given":"Gottfrid","family":"Sj\u00f6dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Steiniche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Mogensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"de Reyni\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Nawroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejan","family":"Dragicevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas G.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshita","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn D.","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay D.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6149-1331","authenticated-orcid":false,"given":"Joshua I.","family":"Warrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Segersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijel","family":"Sikic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim E. M.","family":"van Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Meeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"DeGraff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Knowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Simic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen C.","family":"Zwarthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Uno","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-3784","authenticated-orcid":false,"given":"N\u00faria","family":"Malats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-498X","authenticated-orcid":false,"given":"Francisco X.","family":"Real","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7061-9851","authenticated-orcid":false,"given":"Lars","family":"Dyrskj\u00f8t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"key":"22465_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk, M. et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur. Urol. 71, 447\u2013461 (2017).","journal-title":"Eur. Urol."},{"key":"22465_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","volume":"66","author":"RS Svatek","year":"2014","unstructured":"Svatek, R. S. et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur. Urol. 66, 253\u2013262 (2014).","journal-title":"Eur. Urol."},{"key":"22465_CR3","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/MOU.0000000000000543","volume":"28","author":"L Dyrskj\u00f8t","year":"2018","unstructured":"Dyrskj\u00f8t, L. & Ingersoll, M. A. Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunology. Curr. Opin. Urol. 28, 598\u2013603 (2018).","journal-title":"Curr. Opin. Urol."},{"key":"22465_CR4","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1158\/1078-0432.CCR-04-2095","volume":"11","author":"L Dyrskj\u00f8t","year":"2005","unstructured":"Dyrskj\u00f8t, L. et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin. Cancer Res. 11, 4029\u20134036 (2005).","journal-title":"Clin. Cancer Res."},{"key":"22465_CR5","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1158\/0008-5472.CAN-03-3620","volume":"64","author":"L Dyrskj\u00f8t","year":"2004","unstructured":"Dyrskj\u00f8t, L. et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 64, 4040\u20134048 (2004).","journal-title":"Cancer Res."},{"key":"22465_CR6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.eururo.2017.05.040","volume":"72","author":"L Dyrskj\u00f8t","year":"2017","unstructured":"Dyrskj\u00f8t, L. et al. Prognostic impact of a 12-gene progression score in non-muscle-invasive bladder cancer: a prospective multicentre validation study. Eur. Urol. 72, 461\u2013469 (2017).","journal-title":"Eur. Urol."},{"key":"22465_CR7","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","volume":"18","author":"G Sj\u00f6dahl","year":"2012","unstructured":"Sj\u00f6dahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377\u20133386 (2012).","journal-title":"Clin. Cancer Res."},{"key":"22465_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard, J. et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30, 27\u201342 (2016).","journal-title":"Cancer Cell"},{"key":"22465_CR9","first-page":"1257","volume":"44","author":"Z Gibas","year":"1984","unstructured":"Gibas, Z., Prout, G. R. Jr., Connolly, J. G., Pontes, J. E. & Sandberg, A. A. Nonrandom chromosomal changes in transitional cell carcinoma of the bladder. Cancer Res. 44, 1257\u20131264 (1984).","journal-title":"Cancer Res."},{"key":"22465_CR10","first-page":"8241","volume":"61","author":"M H\u00f6glund","year":"2001","unstructured":"H\u00f6glund, M. et al. Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. Cancer Res. 61, 8241\u20138246 (2001).","journal-title":"Cancer Res."},{"key":"22465_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15, 25\u201341 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"22465_CR12","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-17-2719","volume":"24","author":"KEM van Kessel","year":"2018","unstructured":"van Kessel, K. E. M. et al. Molecular markers increase precision of the european association of urology non-muscle-invasive bladder cancer progression risk groups. Clin. Cancer Res. 24, 1586\u20131593 (2018).","journal-title":"Clin. Cancer Res."},{"key":"22465_CR13","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1158\/1078-0432.CCR-12-1807","volume":"18","author":"CD Hurst","year":"2012","unstructured":"Hurst, C. D., Platt, F. M., Taylor, C. F. & Knowles, M. A. Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. Clin. Cancer Res. 18, 5865\u20135877 (2012).","journal-title":"Clin. Cancer Res."},{"key":"22465_CR14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","volume":"32","author":"CD Hurst","year":"2017","unstructured":"Hurst, C. D. et al. Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency. Cancer Cell 32, 701\u2013715.e7 (2017).","journal-title":"Cancer Cell"},{"key":"22465_CR15","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman, W. H., Zitvogel, L., Saut\u00e8s-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717\u2013734 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"22465_CR16","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1073\/pnas.0611618104","volume":"104","author":"P Sharma","year":"2007","unstructured":"Sharma, P. et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc. Natl Acad. Sci. USA 104, 3967\u20133972 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"22465_CR17","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.eururo.2015.02.021","volume":"68","author":"O Patschan","year":"2015","unstructured":"Patschan, O. et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur. Urol. 68, 824\u2013832 (2015). discussion 835\u20136.","journal-title":"Eur. Urol."},{"key":"22465_CR18","first-page":"69","volume":"29A","author":"PK Lipponen","year":"1992","unstructured":"Lipponen, P. K., Eskelinen, M. J., Jauhiainen, K., Harju, E. & Terho, R. Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur. J. Cancer 29A, 69\u201375 (1992).","journal-title":"Eur. J. Cancer"},{"key":"22465_CR19","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.humpath.2013.01.014","volume":"44","author":"C Ayari","year":"2013","unstructured":"Ayari, C. et al. High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer. Hum. Pathol. 44, 1630\u20131637 (2013).","journal-title":"Hum. Pathol."},{"key":"22465_CR20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1158\/2326-6066.CIR-17-0466","volume":"6","author":"ME Winerdal","year":"2018","unstructured":"Winerdal, M. E. et al. Urinary bladder cancer Tregs suppress MMP2 and potentially regulate invasiveness. Cancer Immunol. Res. 6, 528\u2013538 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"22465_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00345-015-1615-3","volume":"34","author":"T Horn","year":"2016","unstructured":"Horn, T. et al. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J. Urol. 34, 181\u2013187 (2016).","journal-title":"World J. Urol."},{"key":"22465_CR22","doi-asserted-by":"publisher","first-page":"e0204745","DOI":"10.1371\/journal.pone.0204745","volume":"13","author":"R Murai","year":"2018","unstructured":"Murai, R. et al. Prediction of intravesical recurrence of non-muscle-invasive bladder cancer by evaluation of intratumoral Foxp3+ T cells in the primary transurethral resection of bladder tumor specimens. PLoS ONE 13, e0204745 (2018).","journal-title":"PLoS ONE"},{"key":"22465_CR23","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572\u20131573 (2010).","journal-title":"Bioinformatics"},{"key":"22465_CR24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466\u20135 (2006). discussion 475\u20137.","journal-title":"Eur. Urol."},{"key":"22465_CR25","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk, M. et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 Update. Eur. Urol. 76, 639\u2013657 (2019).","journal-title":"Eur. Urol."},{"key":"22465_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/path.4886","volume":"242","author":"G Sj\u00f6dahl","year":"2017","unstructured":"Sj\u00f6dahl, G., Eriksson, P., Liedberg, F. & H\u00f6glund, M. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J. Pathol. 242, 113\u2013125 (2017).","journal-title":"J. Pathol."},{"key":"22465_CR27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2019","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420\u2013433 (2019).","journal-title":"Eur. Urol."},{"key":"22465_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1158\/2326-6066.CIR-15-0274","volume":"4","author":"RF Sweis","year":"2016","unstructured":"Sweis, R. F. et al. Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol. Res. 4, 563\u2013568 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"22465_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10873-y","volume":"10","author":"BD Robinson","year":"2019","unstructured":"Robinson, B. D. et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat. Commun. 10, 2977 (2019).","journal-title":"Nat. Commun."},{"key":"22465_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479\u2013485 (2019).","journal-title":"Nature"},{"key":"22465_CR31","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"22465_CR32","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"22465_CR33","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556.e25 (2017).","journal-title":"Cell"},{"key":"22465_CR34","doi-asserted-by":"publisher","first-page":"a019521","DOI":"10.1101\/cshperspect.a019521","volume":"8","author":"JE Audia","year":"2016","unstructured":"Audia, J. E. & Campbell, R. M. Histone modifications and cancer. Cold Spring Harb. Perspect. Biol. 8, a019521 (2016).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"22465_CR35","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.eururo.2020.06.048","volume":"78","author":"AG Robertson","year":"2020","unstructured":"Robertson, A. G. et al. Identification of differential tumor subtypes of T1 bladder cancer. Eur. Urol. 78, 533\u2013537 (2020).","journal-title":"Eur. Urol."},{"key":"22465_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/3871425","volume":"2018","author":"A Gagliano","year":"2018","unstructured":"Gagliano, A. et al. 8q22.1 Microduplication syndrome: why the brain should be spared? A literature review and a case report. Case Rep. Med. 2018, 1\u20136 (2018).","journal-title":"Case Rep. Med."},{"key":"22465_CR37","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"22465_CR38","doi-asserted-by":"publisher","first-page":"5894","DOI":"10.1158\/0008-5472.CAN-16-0436","volume":"76","author":"P Lamy","year":"2016","unstructured":"Lamy, P. et al. Paired exome analysis reveals clonal evolution and potential therapeutic targets in urothelial carcinoma. Cancer Res. 76, 5894\u20135906 (2016).","journal-title":"Cancer Res."},{"key":"22465_CR39","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ng.3557","volume":"48","author":"J Kim","year":"2016","unstructured":"Kim, J. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet. 48, 600\u2013606 (2016).","journal-title":"Nat. Genet."},{"key":"22465_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09307-6","volume":"10","author":"Y Blum","year":"2019","unstructured":"Blum, Y. et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat. Commun. 10, 1333 (2019).","journal-title":"Nat. Commun."},{"key":"22465_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18640-0","volume":"11","author":"A Taber","year":"2020","unstructured":"Taber, A. et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat. Commun. 11, 4858 (2020).","journal-title":"Nat. Commun."},{"key":"22465_CR42","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer\u2013immune set point. Nature 541, 321\u2013330 (2017).","journal-title":"Nature"},{"key":"22465_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3233\/BLC-150037","volume":"2","author":"SP Lerner","year":"2016","unstructured":"Lerner, S. P. et al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer 2, 37\u201347 (2016).","journal-title":"Bladder Cancer"},{"key":"22465_CR44","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/path.5318","volume":"249","author":"C Bernardo","year":"2019","unstructured":"Bernardo, C. et al. Molecular pathology of the luminal class of urothelial tumors. J. Pathol. 249, 308\u2013318 (2019).","journal-title":"J. Pathol."},{"key":"22465_CR45","doi-asserted-by":"publisher","first-page":"e38863","DOI":"10.1371\/journal.pone.0038863","volume":"7","author":"D Lindgren","year":"2012","unstructured":"Lindgren, D. et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS ONE 7, e38863 (2012).","journal-title":"PLoS ONE"},{"key":"22465_CR46","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613\u2013628 (2017).","journal-title":"Cell"},{"key":"22465_CR47","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/embor.2012.61","volume":"13","author":"N McGranahan","year":"2012","unstructured":"McGranahan, N., Burrell, R. A., Endesfelder, D., Novelli, M. R. & Swanton, C. Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep. 13, 528\u2013538 (2012).","journal-title":"EMBO Rep."},{"key":"22465_CR48","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1038\/onc.2012.381","volume":"32","author":"T Schepeler","year":"2013","unstructured":"Schepeler, T. et al. A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response. Oncogene 32, 3577\u20133586 (2013).","journal-title":"Oncogene"},{"key":"22465_CR49","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1126\/science.1140735","volume":"319","author":"TD Halazonetis","year":"2008","unstructured":"Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352\u20131355 (2008).","journal-title":"Science"},{"key":"22465_CR50","doi-asserted-by":"crossref","unstructured":"Yizhak, K. et al. RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. Science 364, eaaw0726 (2019).","DOI":"10.1126\/science.aaw0726"},{"key":"22465_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1126\/science.1253462","volume":"346","author":"EC de Bruin","year":"2014","unstructured":"de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251\u2013256 (2014).","journal-title":"Science"},{"key":"22465_CR52","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2159-8290.CD-15-0344","volume":"5","author":"C Swanton","year":"2015","unstructured":"Swanton, C., McGranahan, N., Starrett, G. J. & Harris, R. S. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 5, 704\u2013712 (2015).","journal-title":"Cancer Discov."},{"key":"22465_CR53","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s12672-014-0196-8","volume":"5","author":"AM Sieuwerts","year":"2014","unstructured":"Sieuwerts, A. M. et al. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm. Cancer 5, 405\u2013413 (2014).","journal-title":"Horm. Cancer"},{"key":"22465_CR54","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1158\/1078-0432.CCR-06-2940","volume":"13","author":"L Dyrskj\u00f8t","year":"2007","unstructured":"Dyrskj\u00f8t, L. et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin. Cancer Res. 13, 3545\u20133551 (2007).","journal-title":"Clin. Cancer Res."},{"key":"22465_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22126-x","volume":"8","author":"N-A-D Marzouka","year":"2018","unstructured":"Marzouka, N.-A.-D. et al. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci. Rep. 8, 3737 (2018).","journal-title":"Sci. Rep."},{"key":"22465_CR56","unstructured":"Liu, Y. et al. The androgen receptor regulates a druggable translational regulon in advanced prostate cancer. Sci. Transl. Med. 11, eaaw4993 (2019)."},{"key":"22465_CR57","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1593\/tlo.13247","volume":"6","author":"SK George","year":"2013","unstructured":"George, S. K. et al. Chemoprevention of BBN-induced bladder carcinogenesis by the selective estrogen receptor modulator tamoxifen. Transl. Oncol. 6, 244\u2013255 (2013).","journal-title":"Transl. Oncol."},{"key":"22465_CR58","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/carcin\/bgt348","volume":"35","author":"I Hsu","year":"2014","unstructured":"Hsu, I. et al. Suppression of ER\u03b2 signaling via ER\u03b2 knockout or antagonist protects against bladder cancer development. Carcinogenesis 35, 651\u2013661 (2014).","journal-title":"Carcinogenesis"},{"key":"22465_CR59","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.ajpath.2013.01.018","volume":"182","author":"J-W Hsu","year":"2013","unstructured":"Hsu, J.-W. et al. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. Am. J. Pathol. 182, 1811\u20131820 (2013).","journal-title":"Am. J. Pathol."},{"key":"22465_CR60","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","volume":"69","author":"J Dobruch","year":"2016","unstructured":"Dobruch, J. et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur. Urol. 69, 300\u2013310 (2016).","journal-title":"Eur. Urol."},{"key":"22465_CR61","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1200\/jco.2015.33.15_suppl.4502","volume":"33","author":"ER Plimack","year":"2015","unstructured":"Plimack, E. R. et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. J. Clin. Oncol. 33, 4502\u20134502 (2015).","journal-title":"J. Clin. Oncol."},{"key":"22465_CR62","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1200\/jco.2016.34.2_suppl.367","volume":"34","author":"AB Apolo","year":"2016","unstructured":"Apolo, A. B. et al. Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial. J. Clin. Oncol. 34, 367\u2013367 (2016).","journal-title":"J. Clin. Oncol."},{"key":"22465_CR63","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1200\/JCO.2020.38.6_suppl.510","volume":"38","author":"EK Cha","year":"2020","unstructured":"Cha, E. K. et al. Marker lesion study of oral FGFR inhibitor BGJ398 in patients with FGFR3-altered intermediate-risk nonmuscle-invasive bladder cancer. J. Clin. Oncol. 38, 510\u2013510 (2020).","journal-title":"J. Clin. Oncol."},{"key":"22465_CR64","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","volume":"73","author":"AM Kamat","year":"2018","unstructured":"Kamat, A. M. et al. Predicting response to intravesical Bacillus Calmette-Gu\u00e9rin immunotherapy: are we there yet? A systematic review. Eur. Urol. 73, 738\u2013748 (2018).","journal-title":"Eur. Urol."},{"key":"22465_CR65","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.juro.2011.10.144","volume":"187","author":"AM Kamat","year":"2012","unstructured":"Kamat, A. M. et al. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial. J. Urol. 187, 862\u2013867 (2012).","journal-title":"J. Urol."},{"key":"22465_CR66","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","volume":"26","author":"M Kates","year":"2019","unstructured":"Kates, M. et al. Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials. Clin. Cancer Res. 26, 882\u2013891 (2019).","journal-title":"Clin. Cancer Res."},{"key":"22465_CR67","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"22465_CR68","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.celrep.2014.10.035","volume":"9","author":"A Biton","year":"2014","unstructured":"Biton, A. et al. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes. Cell Rep. 9, 1235\u20131245 (2014).","journal-title":"Cell Rep."},{"key":"22465_CR69","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1541-7786.MCR-12-0274","volume":"10","author":"G van der Horst","year":"2012","unstructured":"van der Horst, G., Bos, L. & van der Pluijm, G. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol. Cancer Res. 10, 995\u20131009 (2012).","journal-title":"Mol. Cancer Res."},{"key":"22465_CR70","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/bjc.2012.412","volume":"107","author":"L Dyrskj\u00f8t","year":"2012","unstructured":"Dyrskj\u00f8t, L. et al. Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR. Br. J. Cancer 107, 1392\u20131398 (2012).","journal-title":"Br. J. Cancer"},{"key":"22465_CR71","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.1318376111","volume":"111","author":"JS Damrauer","year":"2014","unstructured":"Damrauer, J. S. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl Acad. Sci. USA 111, 3110\u20133115 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"22465_CR72","doi-asserted-by":"publisher","first-page":"244ra91","DOI":"10.1126\/scitranslmed.3008970","volume":"6","author":"S Rebouissou","year":"2014","unstructured":"Rebouissou, S. et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci. Transl. Med. 6, 244ra91 (2014).","journal-title":"Sci. Transl. Med."},{"key":"22465_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1092-z","volume":"17","author":"Y \u015eenbabao\u011flu","year":"2016","unstructured":"\u015eenbabao\u011flu, Y. et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 17, 231 (2016).","journal-title":"Genome Biol."},{"key":"22465_CR74","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"22465_CR75","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1158\/1078-0432.CCR-17-0038","volume":"23","author":"L Yang","year":"2017","unstructured":"Yang, L. et al. A gene signature for selecting benefit from hypoxia modification of radiotherapy for high-risk bladder cancer patients. Clin. Cancer Res. 23, 4761\u20134768 (2017).","journal-title":"Clin. Cancer Res."},{"key":"22465_CR76","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","volume":"5","author":"P Danaher","year":"2017","unstructured":"Danaher, P. et al. Gene expression markers of tumor infiltrating leukocytes. J. Immunother. Cancer 5, 18 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"22465_CR77","doi-asserted-by":"crossref","unstructured":"Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017).","DOI":"10.1126\/science.aaf8399"},{"key":"22465_CR78","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/ng.3458","volume":"48","author":"MAA Castro","year":"2016","unstructured":"Castro, M. A. A. et al. Regulators of genetic risk of breast cancer identified by integrative network analysis. Nat. Genet. 48, 12\u201321 (2016).","journal-title":"Nat. Genet."},{"key":"22465_CR79","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/labinvest.2017.37","volume":"97","author":"W Zhang","year":"2017","unstructured":"Zhang, W. et al. Fully automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification and same species antibodies. Lab. Invest. 97, 873\u2013885 (2017).","journal-title":"Lab. Invest."},{"key":"22465_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-3","volume":"9","author":"W-J Kim","year":"2010","unstructured":"Kim, W.-J. et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol. Cancer 9, 3 (2010).","journal-title":"Mol. Cancer"},{"key":"22465_CR81","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152\u2013165 (2014).","journal-title":"Cancer Cell"},{"key":"22465_CR82","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ebiom.2019.10.058","volume":"50","author":"B-N Song","year":"2019","unstructured":"Song, B.-N. et al. Identification of an immunotherapy-responsive molecular subtype of bladder cancer. EBioMedicine 50, 238\u2013245 (2019).","journal-title":"EBioMedicine"},{"key":"22465_CR83","doi-asserted-by":"publisher","unstructured":"Sj\u00f6dahl, G. et al. Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma. Int. J. Cancer https:\/\/doi.org\/10.1002\/ijc.32737 (2019) .","DOI":"10.1002\/ijc.32737"},{"key":"22465_CR84","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1074\/mcp.M700590-MCP200","volume":"7","author":"K Thorsen","year":"2008","unstructured":"Thorsen, K. et al. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol. Cell. Proteom. 7, 1214\u20131224 (2008).","journal-title":"Mol. Cell. Proteom."},{"key":"22465_CR85","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1158\/0008-5472.CAN-05-3456","volume":"66","author":"M Aaboe","year":"2006","unstructured":"Aaboe, M. et al. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res. 66, 3434\u20133442 (2006).","journal-title":"Cancer Res."},{"key":"22465_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).","journal-title":"Genome Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22465-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22465-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22465-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T06:41:32Z","timestamp":1669963292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22465-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,16]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["22465"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-22465-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.19.20054809","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,16]]},"assertion":[{"value":"11 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.D. has sponsored research agreements with C2i-genomics, Natera, AstraZeneca and Ferring, and has an advisory\/consulting role at Ferring. J.B.J. has sponsored research agreements with Medac, Photocure ASA, Cephaid, Nucleix, Astellas and Ferring, and has an advisory board role at Olympus Europe, Cephaid and Ferring. J.D.R. is involved in a sponsored scientific study or trial with Pacific Edge Biotechnologies, MDxHealth and Urogen Pharma, is a consultant for Urogen Pharma, and has an investment interest in American Kidney Stone Management. J.J.M. is a consultant for Ferring, AstraZeneca, Janssen and participated in advisory boards for Foundation Medicine and Nucleix. R.T.B. has contributed to advisory boards for Olympus Medical Systems & Janssen, and undertakes research funded by UroGen Pharma and QED Therapeutics. The following authors declare no competing interests: S.V.L., F.P., P.L., A.T., C.S.G., K.B.D., T.S., I.N., E.C., M.S., N.J.B., L.M., G.G.H., A.C.P., V.W., M.O.G., M.H., G.S., M.H., T.S., K.M., A.R., R.M., B.J., X.L., D.D., D.G.W., A.G., C.D.H., J.I.W., U.S., D.S., K.E.M.K., T.M., D.J.D., M.A.K., T.S., A.H., E.C.Z., P.U.M., N.M., and F.X.R.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2301"}}